Free Trial

Bristol-Myers 4Pt Jumbo from 10Y-40Y

PIPELINE

Bristol-Myers helps kick-start high-grade issuance after languishing last few sessions.

  • Date $MM Issuer (Priced *, Launch #)
  • 02/14 $1B Factset WNG 5Y +135a, 10Y +175a
  • 02/14 $Benchmark Bristol-Myers 10Y +115a, 20Y +140a, 30Y +155a, 40Y +170a
  • 02/14 $Benchmark Enbridge 2Y +85a, 2Y FRN/SOFR, 3Y +95a
  • 02/14 $Benchmark Norfolk Southern 10Y +120a, 31Y +155a
  • 02/15 $500M Israel Electric Corp WNG 10Y +200a

For comparison: prior Bristol-Myers jumbo issuance
On Nov 11 '20 Bristol-Myers Squibb $7B 6pt: $1.5B 3NC1 +30, $1B 5Y +35, $1B 7Y +45, $1.25B 10Y +55, $750M 20Y +65, $1.5B 30Y +85.
Prior jumbo issue: total $19B, 9pt on May 7, 2019:
$750M 1.5Y +20, $1B 2Y +35, $1.5B 3Y fix +45, $500M 3Y FRN L+38, $3.25B 5Y +73, $2.25B 7Y +90, $4B 10Y +105, $2B 20Y +30, $3.75B 30Y +145.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.